hiv-1 immunogen
Vaccineexperimental
Clinical trial activity
11 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
5
Phase 3
3
Phase 4
0
Earliest trial started Aug 1, 1995 (NCT00001445)
Timeline
Indications
Studied for
Mechanism of action
- Human immunodeficiency virus type I enhancer-binding protein 1Immunity, active
HIVEP1 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- hiv-1 immunogen
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00021762 | Phase 2 | Aug 4, 2001 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00006495 | Phase 1 | Nov 15, 2000 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00006153 | Phase 1 | Aug 7, 2000 | National Institute of Allergy and Infectious Diseases (NIAID), The Immune Response Corporation |
| NCT00005758 | Phase 3 | May 23, 2000 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00005001 | Phase 2 | Mar 21, 2000 | Agouron |
| NCT00005002 | Phase 3 | Mar 21, 2000 | Agouron |
| NCT00002359 | Phase 3 | Nov 2, 1999 | The Immune Response Corporation |
| NCT00002173 | N/A | Nov 2, 1999 | The Immune Response Corporation |
| NCT00002172 | N/A | Nov 2, 1999 | The Immune Response Corporation |
| NCT00000943 | N/A | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00001445 | Phase 1 | Aug 1, 1995 | National Cancer Institute (NCI) |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 5 | 5 | 4 | 1999 |
| The Immune Response Corporation | For profit | 4 | 3 | 3 | 1999 |
| Agouron | For profit | 2 | 2 | 2 | 2000 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 1995 |
4 organizations
Page 1 / 1